$SERA

Lawrence Sandra AJ sold $3K of SERA

Lawrence Sandra AJ sold 1,560 shares of SERA PROGNOSTICS, INC. (SERA) at $2.15 on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lawrence Sandra AJ
Published Jun 9, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

This is a planned open-market sale by a director under a Rule 10b5-1 plan; such filings are generally low-signal for trading decisions unless they reveal a change in trading behavior or coincide with other material company news.

02

Market read

Low incremental information: a small, pre-arranged director sale with no accompanying fundamental catalyst in the text.

03

What to watch

10b5-1 plans can be executed regardless of company outlook; the disclosed sale size is small, so any inference about fundamentals is weak.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-09; sale executed 2026-06-08.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for SERA Progonostics, Inc.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

SEC Form 4 shows director Lawrence Sandra AJ sold 1,560 SERA shares in an open-market transaction on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move driven solely by this Form 4 sale.

Evidence & confidence

The filing is an insider sale (not a buy), explicitly under a pre-arranged 10b5-1 plan, and the disclosed value (~$3.4K) is small relative to typical market-moving thresholds.

Market effects

None discernible from a small, planned director sale.

None.

None.

Counterpoint

If this director’s 10b5-1 sales are unusually frequent or accelerating, it could reflect private caution—though this single small sale is not enough to confirm that.

Key entities

  • SERA Progonostics, Inc.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Lawrence Sandra AJ

    Director who sold 1,560 shares on 2026-06-08 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t